BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease (NCT05456880)

🧪 Interventions in This Study

• BEAM-101 (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (19 Sites)

• University of Alabama at Birmingham — Birmingham, Alabama
• Phoenix Children's Hospital — Phoenix, Arizona
• Mayo Clinic Florida — Jacksonville, Florida
• University of Miami — Miami, Florida
• Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center - Egleston Hospital — Atlanta, Georgia
• Boston Children's Hospital — Boston, Massachusetts
• Henry Ford Cancer Center — Detroit, Michigan
• University of Minnesota — Minneapolis, Minnesota
• Washington University School of Medicine in St. Louis — St Louis, Missouri
• Hackensack University Medical Center — Hackensack, New Jersey
• Columbia University Irving Medical Center — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• University Hospitals Cleveland Medical Center — Cleveland, Ohio
• The Cleveland Clinic Foundation — Cleveland, Ohio
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
• Medical University of South Carolina — Charleston, South Carolina
• St Jude Children's Research Hospital — Memphis, Tennessee
• The Children's Hospital at TriStar Centennial — Nashville, Tennessee
• Medical College of Wisconsin — Milwaukee, Wisconsin

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Sickle Cell Disease

• Kidney Function in Sickle Cell Anemia — Chapel Hill, North Carolina
• Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease — Bethesda, Maryland
• Acupressure in Patients With Sickle Cell Disease — Irvine, California
• Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) — Chicago, Illinois
• Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) — Charlotte, North Carolina

Explore by condition: All Sickle Cell Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.